Endo, Impax sued by US FTC for allegedly agreeing to eliminate competition for oxymorphone ER
MLex Summary: The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories and Impax’s owner, Amneal Pharmaceuticals, alleging that they illegally conspired to limit competition in the market for oxymorphone...To view the full article, register now.
Already a subscriber? Click here to view full article